A Phase 1, Randomized, Double-blind, Placebo-controlled, Integrated Single Ascending Dose, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
Latest Information Update: 08 Aug 2025
At a glance
- Drugs AMG 691 (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Amgen
Most Recent Events
- 26 Jun 2025 Planned End Date changed from 24 Sep 2026 to 25 Oct 2026.
- 26 Jun 2025 Planned primary completion date changed from 13 Aug 2026 to 13 Sep 2026.
- 13 Jun 2025 Planned End Date changed from 3 Aug 2026 to 24 Sep 2026.